Ofost 10 i.e./ml raztopina za injiciranje/infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ofost 10 i.e./ml raztopina za injiciranje/infundiranje

oksitocin - raztopina za injiciranje/infundiranje - oksitocin 10 i.e. / 1 ml - oksitocin

Ofost 10 i.e./ml raztopina za injiciranje/infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ofost 10 i.e./ml raztopina za injiciranje/infundiranje

oksitocin - raztopina za injiciranje/infundiranje - oksitocin 10 i.e. / 1 ml - oksitocin

Iasibon Evropska unija - slovenščina - EMA (European Medicines Agency)

iasibon

pharmathen s.a. - ibandronska kislina - hypercalcemia; fractures, bone; neoplasm metastasis; breast neoplasms - zdravila za zdravljenje bolezni kosti - concentrate for solution for infusion prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. zdravljenje tumorjev-induced hypercalcaemia z ali brez zasevki. film-coated tablets prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

Ceftazidim Hospira 1 g prašek za raztopino za injiciranje/infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ceftazidim hospira 1 g prašek za raztopino za injiciranje/infundiranje

hospira uk ltd - ceftazidim - prašek za raztopino za injiciranje/infundiranje - ceftazidim 1000 mg / 1 viala - ceftazidim

Ofost 5 i.e./ml raztopina za injiciranje/infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ofost 5 i.e./ml raztopina za injiciranje/infundiranje

oksitocin - raztopina za injiciranje/infundiranje - oksitocin 5 i.e. / 1 ml - oksitocin

Meropenem Kabi 1 g prašek za raztopino za injiciranje ali infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

meropenem kabi 1 g prašek za raztopino za injiciranje ali infundiranje

fresenius kabi deutschland gmbh - meropenem - prašek za raztopino za injiciranje/infundiranje - meropenem 1 g / 1 steklenica - meropenem

Meropenem Kabi 1 g prašek za raztopino za injiciranje ali infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

meropenem kabi 1 g prašek za raztopino za injiciranje ali infundiranje

fresenius kabi deutschland gmbh - meropenem - prašek za raztopino za injiciranje/infundiranje - meropenem 1 g / 1 steklenica - meropenem

Ondansetron Accord 2 mg/ml raztopina za injiciranje ali infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ondansetron accord 2 mg/ml raztopina za injiciranje ali infundiranje

accord healthcare - ondansetron - raztopina za injiciranje/infundiranje - ondansetron 2 mg / 1 ml - ondansetron

Purevax RCP FeLV Evropska unija - slovenščina - EMA (European Medicines Agency)

purevax rcp felv

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Purevax RCPCh Evropska unija - slovenščina - EMA (European Medicines Agency)

purevax rcpch

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. nastopi imunosti so dokazali en teden po primarno cepljenje seveda za rhinotracheitis, calicivirus, chlamydophila felis in panleucopenia komponente. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.